

What is claimed is:

- Claim 1. A vaccine delivery system comprising adjuvant and a plurality of nanoparticles comprising immunogenic antigen or nucleic acid encoding an immunogenic antigen.
- Claim 2. The vaccine delivery system of claim 1 wherein the nanoparticles are cationic.
- Claim 3. The vaccine delivery system of claim 1 wherein the nanoparticles are anionic.
- Claim 4. The vaccine delivery system of claim 1 wherein the nanoparticles are neutral.
- Claim 5. The vaccine delivery system of claim 1 wherein the nanoparticles comprise an anionic surfactant.
- Claim 6. The vaccine delivery system of claim 1 wherein the nanoparticles comprise a cationic surfactant.
- Claim 7. The vaccine delivery system of claim 1 wherein the nanoparticles comprise a neutral surfactant.
- Claim 8. The vaccine delivery system of claim 1 wherein the nanoparticles are coated or admixed with nucleic acid encoding an immunogenic polypeptide.
- Claim 9. The vaccine delivery system of claim 1 wherein the immunogenic antigen is a polypeptide or peptide.

Claim 10. The vaccine of claim 1 wherein the adjuvant is selected from the group consisting of cholera toxin, lipid A, and monophosphoryl lipid A.

Claim 11. The vaccine of claim 1 wherein the adjuvant is cholera toxin.

Claim 12. The vaccine of claim 1 wherein the adjuvant is lipid A or monophosphoryl lipid A.

Claim 13. The vaccine of claim 1 wherein the nucleic acid is DNA.

Claim 14. The vaccine of claim 1 wherein the nucleic acid is an oligonucleotide.

Claim 15. A method of immunizing an animal comprising administering to the animal a vaccine delivery system comprising adjuvant and a plurality of nanoparticles comprising immunogenic antigen or nucleic acid encoding immunogenic antigen.

Claim 16. The method of claim 15 wherein the adjuvant and vaccine are administered simultaneously.

Claim 17. The method of claim 15 wherein the adjuvant is administered within 24 hours of administering the nanoparticles.

Claim 18. The method of claim 15 wherein the vaccine delivery system is administered *via* a non-invasive, parenteral, or mucosal route.

Claim 19.. The method of claim 15 wherein the vaccine delivery system is administered topically.

Claim 20. The method of claim 15 wherein the vaccine delivery system is delivered subcutaneously.

Claim 21. The method of claim 15 wherein the adjuvant is lipid A or monophosphoryl lipid A.

Claim 22. The method of claim 15 wherein the adjuvant is cholera toxin.

Claim 23. The method of claim 15 wherein the nucleic acid is DNA.

Claim 24. The method of claim 15 wherein the nucleic acid is RNA.

Claim 25. The method of claim 15 wherein the nucleic acid is an oligonucleotide.

Claim 26. A method for enhancing a Th1 response in a patient comprising administering a vaccine delivery system comprising adjuvant and a plurality of nanoparticles comprising an immunogenic antigen or nucleic acid encoding an immunogenic antigen to the patient.